Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $381.87, demonstrating a +1.39% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.5%. At ...

In the teaching of computer science, metaphors and analogies are especially fitting: the essence of algorithms is abstract discrete structures, and to help learners quickly grasp the logic within, we ...

Abstract: Human motor learning is a neural process essential for acquiring new motor skills and adapting existing ones, which is fundamental to everyday activities. Neurological disorders such as ...

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...

Vertex also announced enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of ...

Hello, today I’m going to review the Particle Tachyon SBC designed for high-performance edge AI, IoT, and connectivity ...

President Trump announced new tariffs on pharmaceuticals, heavy trucks, and furniture, including a 100% duty on patented drugs, with some exemptions. Thursday's move is one of Trump's new ...

President Trump announced new tariffs on pharmaceuticals, heavy trucks and furniture, including a 100% duty on patented drugs, unless the producer is building a manufacturing plant in the US. Thursday ...

The Rasmussen Reports daily Presidential Tracking Poll for Friday shows that 49% of Likely U.S. Voters approve of President Trump’s job performance. Fifty (50%) disapprove. The latest figures include ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX ® (su ...